IMMUNOSUPPRESSANTS IN THE STATE HEALTHCARE GUARANTEES PROGRAM

Authors

DOI:

https://doi.org/10.11603/2312-0967.2025.2.15443

Keywords:

immunosuppressants, assortment, pharmacy, retail price, reimbursement of cost

Abstract

The aim of the work - to analyze the dynamics of the assortment, reimbursement amount, and price characteristics of immunosuppressants included in the state healthcare guarantees program, and to investigate their consumption using a specific pharmacy as an example.

Materials and Methods. Data on the nomenclature and retail prices of immunosuppressants from five Registers of Medicinal Products Subject to Reimbursement for the period 2023-2025, and information on their sales volumes over 6 months (in natural and monetary terms) from one of Lviv's pharmacies dispensing medicines under this state program. Methods: analysis, comparison, and generalization.

Results and Discussion. It was found that in the period 2023-2025, 5 international non-proprietary names of immunosuppressants were included in the state healthcare guarantees program. At the same time, 56.0% of the assortment items of tacrolimus 24.0% - cyclosporine, 12.0% - mycophenolic acid and its salts, as well as 4.0% each - certican and valacyclovir were included in the latest Register of Medicinal Products Subject to Reimbursement. Immunosuppressants are characterized by complete import dependence. Moreover, for 72.0% of their assortment, only one enterprise is involved in production, while for the rest, three to six enterprises are involved. According to the first three Registers, patients could receive 71.4% of immunosuppressants free of charge, while the rest required partial co-payment. However, in the last two Registers, the share of immunosuppressant assortment positions requiring partial co-payment from the patient increased to 40.0%. Retail prices for 9 (36.0%) assortment positions decreased or remained unchanged, while for 16 (64.0%) they increased. From March to August 2024, the examined pharmacy, which dispenses medicines under the state healthcare guarantees program, sold only two-thirds of the immunosuppressant assortment positions, covering three out of five international non-proprietary names included in the Register. Tacrolimus led in terms of the number of issued e-prescriptions (71.3%), dispensed packages (73.8%), and sales volume in monetary terms (86.0%).

Conclusions. The dynamics of the assortment, reimbursement amount, and price characteristics of immunosuppressants included in the state healthcare guarantees program were analyzed, and the main trends in their sales at the pharmacy level were established.

Author Biographies

S. S. Klymchuk, Danylo Halytsky Lviv National Medical University

student of the Pharmacy Faculty

I. Ya. Horodetska, Danylo Halytsky Lviv National Medical University

PhD  (Pharmacy), Associate Professor, Associate Professor of the Organization and Economics of Pharmacy Department

O. R. Levytska, Danylo Halytsky Lviv National Medical University

DSс (Pharmacy), Professor, Professor of the Organization and Economics of Pharmacy Department

B. P. Hromovyk, Danylo Halytsky Lviv National Medical University

DSc (Pharmacy), Professor, Head of the Organization and Economics of Pharmacy Department

References

On the introduction of reimbursement of the cost of medicines. [Internet]. Resolution of the Cabinet of Ministers of Ukraine. Order No. 863 (2016). Available from: https://zakon.rada.gov.ua/laws/show/863-2016-%D0%BF#Text. Ukrainian.

For the approval of the Register of medical institutions eligible for reimbursement for the program of state guarantees of medical care for the population, as of February 14, 2023. [Internet]. Ministry of Health of Ukraine. Order No. 351 (2023). Available from: https://zakon.rada.gov.ua/rada/show/v0351282-23#Text. Ukrainian/

Immunosuppressants have been added to the list of medicines that are reimbursed. [Internet]. Ministry of Health of Ukraine. Available from: https://moz.gov.ua/uk/imunosupresanti-dodano-do-pereliku-likarskih-zasobiv-jaki-pidljagajut-reimbursacii . Ukrainian.

Statistics 2024. [Internet]. Ukrainian Transplant Coordination Center. Available from: https://utcc.gov.ua/statystyka/statystyka-2024/. Ukrainian.

Tkachova OV, Nohachevska H.V. Immunosupressive means: study of assortment and consumption in Ukraine. Management, economy and quality assurance in pharmacy. 2019;2(58):70-5. DOI: 10.24959/uekj.19.18 Ukrainian. DOI: https://doi.org/10.24959/uekj.19.18

Brukh MI, Levytska OR, Horodetska IYa, Korniyenko OM, Hromovyk BP. Immunomodulators as objects of the pharmaceutical market. Message III. The product conjuncture of immunosuppressants and their place in the state guarantees program of medical care of the population]. Farmatsevtychnyy zhurnal. 2023;78(6): 3-14. DOI: 10.32352/0367-3057.6.23.01. Ukrainian. DOI: https://doi.org/10.32352/0367-3057.6.23.01

For approval of the Register of medical facilities eligible for reimbursement for the program of state guarantees of medical care for the population, as of August 10, 2023. [Internet]. Ministry of Health of Ukraine. Order No. 1495 (2023). Available from: https://zakon.rada.gov.ua/rada/show/v1495282-23#Text. Ukrainian.

For the approval of the Register of medical institutions eligible for reimbursement for the program of state guarantees of medical care for the population, as of February 12, 2024. [Internet]. Ministry of Health of Ukraine. Order No. 279 (2024). Available from: https://surl.li/iusnlo. Ukrainian.

For the approval of the Register of medical institutions eligible for reimbursement under the program of state guarantees of medical care for the population, as of December 23, 2024. [Internet]. Ministry of Health of Ukraine. Order No. 2148 (2024). Available from: https://surl.li/cqecrw. Ukrainian.

For the approval of the Register of medical institutions eligible for reimbursement for the program of state guarantees of medical care for the population, as of February 26, 2025. [Internet]. Ministry of Health of Ukraine. Order No. 440 (2025). Available from: https://surl.lu/cianwd. Ukrainian.

Handbook of medical drugs Compendium. [Internet]. Available from: https://compendium.com.ua/uk/atc/l/. Ukrainian.

State Register of Medicinal Products of Ukraine. [Internet]. Available from: http://www.drlz.com.ua/. Ukrainian.

Tacrolimus Global Market Report 2025 – By Product Type, By Application, By End User–Market Size, Trends, And Global Forecast 2025-2034. [Internet]. Available from: https://surli.cc/tzozrg.

Guideline 00231. Transplant recipient patient in primary care. [Internet]. Available from: https://guidelines.moz.gov.ua/documents/3119. Ukrainian.

Downloads

Published

2025-06-30

How to Cite

Klymchuk, S. S., Horodetska, I. Y., Levytska, O. R., & Hromovyk, B. P. (2025). IMMUNOSUPPRESSANTS IN THE STATE HEALTHCARE GUARANTEES PROGRAM. Pharmaceutical Review Farmacevtičnij časopis, (2), 49–57. https://doi.org/10.11603/2312-0967.2025.2.15443

Issue

No. 2 (2025)

Section

Pharmaceutical management, marketing and logistics

License

Copyright (c) 2025 Pharmaceutical Review / Farmacevtičnij časopis

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The authors who publish their materials in this journal agree with the following terms:

  • Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal Результат пошуку зображень за запитом "CC-BY logo".
  • Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.

Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).